CN101322810A - Chinese traditional medicine composition for treating diabetes respiratory tract infection - Google Patents
Chinese traditional medicine composition for treating diabetes respiratory tract infection Download PDFInfo
- Publication number
- CN101322810A CN101322810A CNA2008100510314A CN200810051031A CN101322810A CN 101322810 A CN101322810 A CN 101322810A CN A2008100510314 A CNA2008100510314 A CN A2008100510314A CN 200810051031 A CN200810051031 A CN 200810051031A CN 101322810 A CN101322810 A CN 101322810A
- Authority
- CN
- China
- Prior art keywords
- portions
- group
- clear
- extract
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 37
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 11
- 229930003935 flavonoid Natural products 0.000 claims description 9
- 150000002215 flavonoids Chemical class 0.000 claims description 9
- 235000017173 flavonoids Nutrition 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002155 anti-virotic effect Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000334154 Isatis tinctoria Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000014676 Phragmites communis Nutrition 0.000 abstract 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 66
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 238000012360 testing method Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000009916 yin-huang Substances 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 230000023555 blood coagulation Effects 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 210000000436 anus Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 206010035664 Pneumonia Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 241001591005 Siga Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010035742 Pneumonitis Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 229940100050 virazole Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940104027 chlorpromazine 25 mg Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229950005770 hyprolose Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medical composition for treating upper respiratory tract infection, which pertains to a TCM (traditional Chinese medicine) composition. The medical composition comprises the following active substances in proportion by weight: 4 portions to 15 portions of aqueous extract of gypsum, 15 portions to 40 portions of Dyers Woad Leaf extract, 12 portions to 40 portions of total flavone of mulberry leaves, 12 portions to 40 portions of reed rhizome extract and 15 portions to 40 portions of liquorice extract. The medical composition of the invention is applicable to the treatment of the upper respiratory tract infection, and has the functions of antipyretic and analgesic, antivirus and anti-infection.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition.Be used for the treatment of upper respiratory tract infection.
Background technology
Upper respiratory tract infection is adult and children's's commonly encountered diseases, frequently-occurring disease, all can take place throughout the year, but with winter-spring season for seeing more, in the annual urban children of China ill per capita 3～6 times, ill per capita 2～5 times of rural children, its cause of disease mostly is virus, still weary at present desirable effectively treatment Western medicine, as nurse improperly, complication or lower respiratory infections such as pharyngolaryngitis easily take place, the serious harm child health.Previously experience and in recent years result of study show that Chinese medicine has its special advantages to the treatment of last sense.The long-pending long-term clinical experience of Xijing hospital Pediatrics Department is formed and is dredged clear side, through dosage forms such as decoct, concentrated decotion, granules, updates raising, surplus the clinical practice ten year, has obtained good result.Carry out experimentation in view of the above, make thin clear granule more become perfect, bring into play bigger social benefit,, promote the well-being of mankind for vast pediatric patient service.
Summary of the invention
The invention provides a kind of pharmaceutical composition, be used for the treatment of upper respiratory tract infection.
Infant upper respiratory tract infection, clinical visible heating, watery nasal discharge, cough, headache, sweating, thirsty, disease such as pharynx is red, the traditional Chinese medical science is referred to as fever caused by exogenous pathogens, according to clinical difference of seeing disease, is divided into wind heat, wind and cold two major types.The affection due to external wind and heat pathogenic factor is many goes into from mouth and nose, the lung position is the highest, stand in the breach, so this onset of disease is the pathological changes center with heresy at lung meridian, heresies such as clinical visible heating is heavy, aversion to cold is light, antiperspirant, headache, nasal obstruction, watery nasal discharge, sneeze are arranged, cough, spit, swallow red, xerostomia, tongue tip side of red, white and thin fur, floating and rapid pulse, floating superficial venule of the index finger dew are attacked lung and are defended syndrome.Because the physiologic factor that the young the moon of children's does not fill, young sun is long, it is comparatively of short duration that syndrome of WEI system is waited majority, and pathogenic heat are interior rapidly to be passed, the syndrome that is heat stagnation lung stomach, said as Chen Ping uncle: " pathogenic wind-warm be a disease, and the moon in spring and winter are in the majority; or aversion to wind or aversion to wind not, must fever of the body cough, excessive thirst ".Clinical manifestation be heating, sweating, headache, cough, watery nasal discharge, agitation, thirsty, pharynx is red, red tongue, the little Huang of tongue, full and rapid pulse, the purplish red floating dew of fingerprint etc., according to this pathogenesis and clinical syndrome characteristics, we have invented by what Gypsum Fibrosum water extract, Folium Isatidis extract, Folium Mori total flavonoids, Rhizoma Phragmitis extract, Radix Glycyrrhizae extractum were formed has heat-clearing and toxic substances removing, leads the Chinese medicine composition of lung stomach function off, with removing summer-heat lung gastric heat heresy, reach the purpose of curing infant upper respiratory tract infection.
The technical scheme that the present invention takes is: include the active substance by following ratio of weight and number:
Gypsum Fibrosum water extract 4-15 part, Folium Isatidis extract 15-40 part, Folium Mori total flavonoids 12-40 part, Rhizoma Phragmitis extract 12-40 part, Radix Glycyrrhizae extractum 15-40 part.
Above-mentioned various extracts among the present invention can be by extracting method acquisition arbitrarily in the prior art.Be preferably: the Gypsum Fibrosum water extract: it is an amount of to take by weighing Gypsum Fibrosum, pulverizes, and with water extraction 1-3 time, adds 6-30 at every turn and doubly measures, decocted 1-4 hour, and filtration, merging filtrate, concentrated.
Folium Isatidis extract: it is an amount of to get Folium Isatidis, with 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocted 0.5-3 hour, and filtration, merging filtrate, concentrated.
Folium Mori total flavonoids: it is an amount of to get Folium Mori, uses 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Rhizoma Phragmitis extract: it is an amount of to get Rhizoma Phragmitis, uses 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Radix Glycyrrhizae extractum: official method.
The present invention can be mixed with medicament with one or more pharmaceutically acceptable carriers or adjuvant.
Above-mentioned pharmaceutically acceptable carrier is meant the pharmaceutical carrier or the adjuvant of pharmaceutical field routine, for example: diluent, excipient and water etc., filler such as starch, dextrin, sucrose, mannitol, lactose, microcrystalline Cellulose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol: disintegrating agent such as methyl starch sodium, hyprolose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol, Tween 80, sodium lauryl sulphate; Alms bowl such as Kaolin and soap clay are carried in absorption; Lubricant such as Pulvis Talci, calcium stearate and magnesium, micropowder silica gel and Polyethylene Glycol etc.In medicament, can also contain other adjuvant such as flavouring agent, sweeting agent etc. in addition.
The medicament that the present invention makes can be applied to the patient by the mode of oral, rectum or parenteral.Be used for when oral, can be made into conventional solid preparation such as tablet, capsule, powder, granule etc., make other liquid preparation of liquid preparation such as water or oil-suspending agent such as syrup, mixture, elixir etc.; When being used for parenteral, can be made into solution, powder pin, water or the oiliness suspending agent etc. of injection.The preferred form of the present invention is tablet, coated tablet, capsule, granule, mixture and powder pin, injection.
The amount of application of the present invention and medicament thereof can be according to variations such as the type of route of administration, patient age, body weight, the disease of being treated and the orders of severity, and its daily dose can be 1.5g～45g, preferred 3g～30g.Can use by one or many.
The present invention is applied to treat upper respiratory tract infection, has antipyretic-antalgic, antiviral, anti-infective effect.
The specific embodiment
Further verify the present invention below by Pharmacodynamic test of active extract.
One, of the present inventionly separates heat test
(1), the present invention is to the rabbit experiment refrigeration function
[test objective] observes the present invention to refrigeration function normal and the heating animal
[being subjected to the reagent thing] medicine of the present invention, hereinafter to be referred as thin clear granule, Jilin Huakang Pharmaceutical Co., Ltd produces, lot number: 021010, every Bao Shuqing granule is equivalent to crude drug 15 grams.
Solvent: distilled water
Compound method: get the thin clear granule of 37.56g and add water to 100ml, be made into suspension, standby.
[animal]
Animal origin is in The Fourth Military Medical University's animal center, the purebred rabbit of New Zealand, the quality certification number: No. 03, the moving card of Shan doctor word.
Sex:
Male, body weight: 1.6～2.2kg, 12 of every group of rabbit.
Separate heat test in [experimental technique selection] selective body.With typhoid fever, pair typhoid fever first and second triple vaccinies is the pyrogenicity agent, the Lanzhou biochemical-pharmaceutical factory.Lot number: 020810
[test key step]
1, to the influence of normal rabbit body temperature
Select body temperature to supply experiment to use 15 of 38.2 ℃～39 ℃ purebred rabbit of New Zealand.Be divided into the normal saline group at random, dredge clear groups of grains, chlorpromazine group, 5 every group.Dredge clear groups of grains and irritate stomach and dredge clear granule 5.4g/kg, the saline group is irritated stomach normal saline 10ml/kg, and chlorpromazine group is irritated stomach chlorpromazine 25mg/kg, and each group was surveyed the anus temperature once every 1 hour, is surveyed the anus temperature and basic anus using warming therapy difference is the index of variation with different time.
2, to the influence of triple vaccine pyrogenicity rabbit body temperature
Select body temperature to supply experiment to use 60 of 33 ℃～38.9 ℃ purebred rabbit of New Zealand.Being divided into 5 groups at random is normal saline group, thin clear granule three groups of (high, medium and low dosage), aspirin groups, ear vein injection triple vaccine 0.8ml/kg, after treating that animal heat rising difference reaches 0.8 ℃, dredge three groups of clear granules and irritate stomach 5.4g/kg, 2.8g/kg, the thin clear granule of 1.4g/kg respectively, the aspirin group is irritated stomach 0.37g/kg aspirin, the normal saline group is irritated stomach 10ml/kg normal saline, surveyed the anus temperature every 1 hour once, surveyed the anus temperature and basic anus using warming therapy difference is the index of body temperature variation with different time.
[animals administer afterreaction]
Observation index: the anus temperature changes after the rabbit administration.
Observing time: administration timing in 30 minutes, observed altogether 5 hours, surveyed the anus temperature once every 1 hour.
Dosage is provided with: 3 dosage groups, heavy dose of group 5.4g/kg, middle dosage group 2.3g/kg, small dose group 1.4g/kg.
[medication] gastric infusion, administration number of times 1 time.
[experimental control] blank is a normal saline.
Positive control medicine: aspirin, lot number 020802, Northwest Synthetic Pharmaceutics Factory No.2.Dosage 0.37g/kg.Chlorpromazine, lot number: 010425, Xi'an pharmaceutical factory.Dosage 25mg/kg.
[result of the test]
1, thin clear granule, normal saline do not have influence to normal animal heat, and chlorpromazine can make intact animal's body temperature descend, and average fall is 0.41 ℃ ± 0.23, and sustainable 3 hours.See Table 1.
Table 1, dredge of the influence (X ± S ℃ n=5) of clear granule to normal rabbit body temperature
Compare with basal body temperature after the medication
*P＜0.05
*P＜0.01
2, dredge three groups of clear granule 5.4g/kg, 2.3g/kg and 1.4g/kg the pyrogenicity rabbit was all produced remarkable cooling effect in 3 hours after administration, compare significant difference (P＜0.05) with the normal saline group, significant difference (P＜0.01) is compared in the cooling effect of aspirin group with the normal saline group, its temperature-fall period is faster than thin clear granule, and effect is strong, and both compare significant difference (P＜0.01) and see Table 2.
Table 2 is dredged the influence (X ± S n=12) of clear granule to rabbit body temperature due to the pyrogenicity agent
Compare with the normal saline group
*P＜0.05
*P＜0.01
Two, dredge the experimentation of clear granule antivirus action
(1), dredges clear granule to the influence of influenza virus in the Embryo Gallus domesticus internal breeding
[test objective] observed and dredged the inhibitory action of clear granule to the Embryo Gallus domesticus inner virus
[being subjected to the reagent thing] dredges clear granule, and Jilin Huakang Pharmaceutical Co., Ltd produces, lot number: 021010, and every Bao Shuqing granule contains dredges clear paste 3.7 grams, is equivalent to crude drug 15 grams.
Solvent: distilled water
Collocation method: take by weighing and dredge clear paste 40g, prepare the test sample liquid of 40% concentration, it is standby to sterilize.
[Embryo Gallus domesticus] enjoys instar chicken embryos on the 10th of egg.
[experimental technique]
Get 100 pieces of Embryo Gallus domesticus, be divided into 5 groups at random, promptly the normal saline group, dredge 40% group of clear granule, dredge 20% group of clear granule, YINHUANG KOUFUYE group, the virazole group is inoculated 20EiD with chick embryo allantoic cavity
50Influenza virus A
3, the anti-90-15 of Ji, after room temperature is placed 1h, normal saline group allantoic cavity gives normal saline 0.1ml, virazole group allantoic cavity gives 2% virazole solution 0.1ml, the YINHUANG KOUFUYE allantoic cavity gives former times of liquid 0.1ml, dredge clear groups of grains and give 40% and each 0.1ml of test sample liquid of 20% two kind of dosage, paraffin sealing, Embryo Gallus domesticus is put hatching in 37 ℃ of incubators, day by day stir, Embryo Gallus domesticus moves to and places 2h in 4 ℃ of refrigerators behind the 72h, gets allantoic fluid and carries out hemagglutination test with 1% chicken red blood cell, positive person does not have antivirus action with blood clotting, and the blood clotting negative patient has antivirus action.
[dosage setting] dredged 40% group of clear granule, dredged 20% group of two dosage group of clear granule
[medication] allantoic cavity drug administration by injection, administration 1 time.
[experimental control] blank group: normal saline.Positive drug contrast: 1. virazole, lot number: 020707, Wuxi City the 7th pharmaceutical factory has the broad-spectrum antiviral performance, and influenza virus A and B are had inhibitory action.2. YINHUANG KOUFUYE, lot number: 020907, southern Shandong pharmaceutical factory has effect similar to this medicine and purposes.
[experimental result] sees Table 3.
Normal saline group Sanguis Gallus domesticus coagulates positive 20 pieces, negative 0 piece of blood clotting, and positive 3 pieces of virazole group blood clotting, negative 17 pieces of blood clotting through X 2 test, is compared significant difference (P＜0.01) with the saline group.Positive 5 pieces of YINHUANG KOUFUYE group blood clotting, negative 12 pieces of blood clotting, compare significant difference (P＜0.05) with the saline group, dredge positive 4 pieces of 40% group of blood clotting of clear granule, negative 16 pieces of blood clotting, compare significant difference (P＜0.01) with the normal saline group, dredge positive 8 pieces of 20% group of blood clotting of clear granule, negative 12 pieces of blood clotting, compare significant difference (P＜0.05) with the saline group, dredge clear granule two dosage groups inhibitory action intensity of influenza virus in the Embryo Gallus domesticus and 2% virazole and former times of YINHUANG KOUFUYE action intensity similar (P＜0.05).
Table 3 is dredged the inhibitory action of clear granule to the Embryo Gallus domesticus inner virus
*P＜0.05
*P＜0.01 is compared with the normal saline group
[conclusion] dredged 40% group of clear granule and dredged 20% group of clear granule has the effect of inhibition influenza virus in the Embryo Gallus domesticus internal breeding, and its heavy dose of group of effect is similar to virazole, and small dose group is similar to YINHUANG KOUFUYE.
(2), dredge clear granule to pneumonitis virus Fm
100The protective effect of infecting mouse
[test objective] observed and dredged clear granule antivirus action in vivo
[being subjected to the medicine medicine]
Title: dredge clear granule
The unit of providing: Jilin Huakang Pharmaceutical Co., Ltd
Lot number: 021010
Content, preparation labelled amount: every Bao Shuqing granule contains dredges clear paste 3.7 grams, is equivalent to crude drug 15 grams.
Solvent: distilled water
Compound method: take by weighing and dredge clear paste 54g, add water to 100ml and stir evenly, standby.
[animal]
The Kunming white mice, The Fourth Military Medical University's animal center.The quality certification number: No. 03, the moving card of Shan doctor word.
Sex, male and female half and half.Body weight: 18～25 grams.
Each treated animal number: 32 of every treated animals, only dredging clear granule 1.4g/kg group is 20.
[experimental technique selection] interior resisting virus effect.
[test key step]
Pneumonia disease strain Fm
100Inoculated into chick embryo goes down to posterity and makes it titre is 1: 640, and it is standby that the packing bottle is placed-20 ℃ of refrigerators.148 of mices are divided into 5 groups at random: normal saline group, thin clear granule 5.4g/kg group, thin clear granule 2.8g/kg group, thin clear granule 1.4g/kg organize, the YINHUANG KOUFUYE group.The mice etherization slowly splashes into titre 1: 640Fm to nasal cavity immediately
10050ul, mice is placed what in the dried and clean mouse cage, infecting beginning normal saline group on the firstth irritates stomach day by day and gives normal saline 20ml/kg, dredge each group of clear granule and irritate the thin clear granule that stomach gives 5.4g/kg, 2.8g/kg, 1.4g/kg three dosage respectively day by day, the YINHUANG KOUFUYE group is irritated stomach and is given YINHUANG KOUFUYE 20ml/kg.Successive administration observes and adds up the survival rate of each treated animal in 10 days after 7 days.
[experimental control] blank assay contrast: normal saline, positive control drug: YINHUANG KOUFUYE.
[result of the test] from infecting the 3rd, normal saline group mice produces and shivers, alarms hair, the tired group of shortening into, dyspnea, and pink blood appears in oral cavity, nasal cavity, and is dead because of pulmonary edema at last.Dredge clear granule 5.4g/kg group part mice and produce symptom same as described above, compare with the normal saline group, through chi-square statistics, significant difference is dredged clear granule 2.8g/kg group and is compared significant difference with the normal saline group.Dredge clear granule 1.4g/kg group and do not have significant difference with the normal saline group.The anti-Fm of YINHUANG KOUFUYE
100Virus function is similar to thin clear heavy dose of group, compares P＜0.01 with the normal saline group.The result shows, dredges clear granule 5.4g/kg, 2.8g/kg and YINHUANG KOUFUYE to pneumonitis virus Fm
100Mice has significant protective effect.See table 4 for details
Table 4 is dredged the protective effect of clear granule to pulmonary infection virus mice
Compare with normal saline
*P＜0.05
*P＜0.01
[conclusion] dredged clear granule 40% and with thin 20% liang of dosage group of clear granule the pneumonitis virus mice had protective effect significantly under this experiment condition, and its exercising result is similar to YINHUANG KOUFUYE, and dredges clear 1.4g/kg group to the effect of pneumonitis virus mice unprotect.
(3), dredge of the research of clear granule to human organism's immunoregulation effect
[test objective] dredges the effect that clear granule has heat-clearing and toxic substances removing, leads the lung stomach off.Clinical to be used for the treatment of the effect of feeling, bring down a fever remarkable, and curative effect preferably such as the course of disease of shortening is arranged.We in zoopery and cell in vitro culture studies, prove that it has the effect of bringing down a fever, suppressing virus multiplication and improve lymhocyte transformation rate.
[object and method]
One, object of study
1, case is selected: select to be diagnosed as the viral infant of going up sense or pneumonia at random.Clinical diagnostic criteria by " new drug (Chinese medicine) treatment infantile fever caused by exogenous pathogens clinical research guideline ", " practical paidonosology ".
2, case grouping: be divided at random and 1. dredge clear groups of grains: 33 examples, age February～3 year old.Removing conventional therapy adds with dredging clear particulate oral.2. matched group: 31 examples, age February～3.1 year old; Except that the conventional method treatment, without other drug.The check of method by statistics, each factor does not have significant difference between two groups.
3, specimen is taked: each is organized patient and all gathered venous blood specimen and saliva on the 3rd day in treatment, and handles specimen by the requirement of research method immediately, carries out related detection.
Two, main agents and research method
1, main agents: 1. mouse-anti-human T
1, T
4, T
8, IFN-γ McAb, prepare mouse ascites fluid with cell strain, extract antibody.2. alkali phosphatase---alkali resistance phosphatase test kit: available from Military Medical Science Institute.3. lymphocyte separation medium: be Shanghai reagent two factory's products.4.
3H-TdR is provided by Shanghai Atomic Nucleus Inst., Chinese Academy of Sciences, emission ratio intensity 25CI/mM.5. the anti-people SIgA of lyophilizing horse diagnostic serum: available from Beijing Biological Product Inst..2, method: the 1. detection of T cell subsets and IFN-γ express cell: adopt APAAP immunoenzyme staining technique, the method for pressing bibliographical information.2. lymphocyte transformation test: adopt
3H-TdR participates in method.3. SIgA content in saliva Determination on content: adopt agar diffusion method.
[result]
1, T cell subsets testing result
As shown in table 5, take thin clear groups of grains and matched group when treating the 3rd day, periphery blood T cell T
3, T
4, T
8The numerical value of subgroup and T
4/ T
8Ratio does not have significant difference.But collecting 3 routine specimen after 1 week with thin clear granule therapy, testing result shows that sick viral infection just causes T
3, T
4, T
8The cell minimizing is significantly recovered.
Table 5 t lymphocyte subsets of peripheral blood testing result (percentage ratio)
2, dredge clear granule to the expression of peripheral blood IFN-gamma cells, lymphocyte transformation and the excretory influence of SIgA: as shown in Table 6, dredge clear groups of grains IFN-gamma cells express cell number apparently higher than matched group.Dredge clear granule and can promote lymphocyte transformation function and saliva SigA secretion, relatively there were significant differences with matched group.
Table 6 is dredged clear granule commentaries on classics and the excretory influence of SIgA are expressed, drenched to the IFN-gamma cells
(4), dredge of the effect of clear granule to antibacterial
[test objective] observed and dredged clear granule antibacterial action
[being subjected to the reagent thing] dredges clear granule
The unit of providing: Jilin Huakang Pharmaceutical Co., Ltd
Lot number: 021010
Content, preparation labelled amount: dredge clear grain density D=1.38,30 ℃ of calorimetric temperature.
[compound method] got and dredged clear granule 60 grams, 40 grams, 20 grams, 10 grams and add respectively that distilled water is made into 60%, 40%, 20%, the need testing solution of 10% 4 kind of variable concentrations, and be aseptic, standby.
[strain] golden staphylococci, pneumobacillus, bacillus pyocyaneus, escherichia coli are provided and are identified by Affiliated Hospital of The Fourth Military Medical University Bacteriology Room.
[test method] scraped and got the lawn that oese was cultivated through 24 hours, be inoculated in agar surface in two dish, then put into Stainless Steel Oxford cuvette, put 6 in each two dish, one is injected normal saline, and one is injected the 1000u penicillin sodium, surpluss 4 thin clear particle solution of injecting variable concentrations, two dish were carefully put incubator 48 hours, take out and measure each bacteriostatic diameter.
[result of the test] thin clear granule four concentration groups see Table 7 to the inhibitory action of antibacterial.
Table 7 is dredged clear granule to the effect of part antibacterial (n=3X X ± S)
Conclusion: this experiment shows, it is invalid substantially to bacterial action to dredge clear granule, though golden staphylococci, pneumobacillus, escherichia coli have certain inhibition zone, the inhibition zone under the high concentration is suspicious, may be that high concentration medicine makes due to the environment change of bacterial growth.
Embodiment 1
4 parts of Gypsum Fibrosum water extracts, 15 parts of Folium Isatidis extracts, 12 parts of Folium Mori total flavonoids, 12 parts of Rhizoma Phragmitis extracts, 15 parts of Radix Glycyrrhizae extractum.
Each extract is mixed, add the conventional adjuvant of preparation tablet, tabletting is made tablet.
Above-mentioned various extracts among the present invention can be by extracting method acquisition arbitrarily in the prior art.Be preferably: the Gypsum Fibrosum water extract: it is an amount of to take by weighing Gypsum Fibrosum, pulverizes, and with water extraction 1-3 time, adds 6-30 at every turn and doubly measures, decocted 1-4 hour, and filtration, merging filtrate, concentrated.
Folium Isatidis extract: it is an amount of to get Folium Isatidis, with 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocted 0.5-3 hour, and filtration, merging filtrate, concentrated.
Folium Mori total flavonoids: it is an amount of to get Folium Mori, uses 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Rhizoma Phragmitis extract: it is an amount of to get Rhizoma Phragmitis, uses 40-90% alcohol reflux 1-3 time, adds 6-20 times of ethanol at every turn, decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Radix Glycyrrhizae extractum: official method.
Embodiment 2
10 parts of Gypsum Fibrosum water extracts, 28 parts of Folium Isatidis extracts, 26 parts of Folium Mori total flavonoids, 26 parts of Rhizoma Phragmitis extracts, 28 parts of Radix Glycyrrhizae extractum.
Each extract is mixed, add the conventional adjuvant of preparation granule, granulate, make granule.
Embodiment 3
15 parts of Gypsum Fibrosum water extracts, 40 parts of Folium Isatidis extracts, 40 parts of Folium Mori total flavonoids, 40 parts of Rhizoma Phragmitis extracts, 40 parts of Radix Glycyrrhizae extractum.
Each extract is mixed, add the conventional adjuvant of preparation granule, granulate, incapsulate, make capsule.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of upper respiratory tract infection is characterized in that including the active substance by following ratio of weight and number:
Gypsum Fibrosum water extract 4-15 part, Folium Isatidis extract 15-40 part, Folium Mori total flavonoids 12-40 part, Rhizoma Phragmitis extract 12-40 part, Radix Glycyrrhizae extractum 15-40 part.
2, the pharmaceutical composition of treatment upper respiratory tract infection as claimed in claim 1 is characterized in that including the active substance by following ratio of weight and number:
10 parts of Gypsum Fibrosum water extracts, 28 parts of Folium Isatidis extracts, 26 parts of Folium Mori total flavonoids, 26 parts of Rhizoma Phragmitis extracts, 28 parts of Radix Glycyrrhizae extractum.
3, the application of pharmaceutical composition as claimed in claim 1 in the medicine of preparation antipyretic-antalgic.
4, the application of pharmaceutical composition as claimed in claim 1 in the preparation antiviral drug.
5, the application of pharmaceutical composition as claimed in claim 1 in preparation anti-infective medicine.
6, the application of pharmaceutical composition as claimed in claim 1 in the medicine of preparation adjusting immunity of organism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100510314A CN101322810B (en) | 2008-07-30 | 2008-07-30 | Chinese traditional medicine composition for treating diabetes respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100510314A CN101322810B (en) | 2008-07-30 | 2008-07-30 | Chinese traditional medicine composition for treating diabetes respiratory tract infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101322810A true CN101322810A (en) | 2008-12-17 |
| CN101322810B CN101322810B (en) | 2011-06-15 |
Family
ID=40186610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100510314A Active CN101322810B (en) | 2008-07-30 | 2008-07-30 | Chinese traditional medicine composition for treating diabetes respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101322810B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920944A (en) * | 2012-11-22 | 2013-02-13 | 吉林华康药业股份有限公司 | Application of Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens |
| CN103223125A (en) * | 2013-05-20 | 2013-07-31 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine composition used for treating chronic bronchitis |
| CN105031379A (en) * | 2015-09-07 | 2015-11-11 | 曹志升 | Traditional Chinese medicine preparation used for treating upper respiratory tract infection and preparation method |
| CN106511585A (en) * | 2016-12-05 | 2017-03-22 | 韦昌仕 | Traditional Chinese medicine composition for treating viral pneumonia |
| CN116059229A (en) * | 2023-03-28 | 2023-05-05 | 吉林华康药业股份有限公司 | Pharmaceutical composition for preventing and treating new coronavirus infection, and medicine and application thereof |
| CN116637158A (en) * | 2023-06-02 | 2023-08-25 | 陕西中医药大学第二附属医院 | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123170A (en) * | 1994-11-18 | 1996-05-29 | 吕建京 | Children's oral-medicine for clearing away heat and toxic material and preparation technology thereof |
-
2008
- 2008-07-30 CN CN2008100510314A patent/CN101322810B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920944A (en) * | 2012-11-22 | 2013-02-13 | 吉林华康药业股份有限公司 | Application of Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens |
| CN103223125A (en) * | 2013-05-20 | 2013-07-31 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine composition used for treating chronic bronchitis |
| CN103223125B (en) * | 2013-05-20 | 2014-08-06 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine composition used for treating chronic bronchitis |
| CN105031379A (en) * | 2015-09-07 | 2015-11-11 | 曹志升 | Traditional Chinese medicine preparation used for treating upper respiratory tract infection and preparation method |
| CN106511585A (en) * | 2016-12-05 | 2017-03-22 | 韦昌仕 | Traditional Chinese medicine composition for treating viral pneumonia |
| CN116059229A (en) * | 2023-03-28 | 2023-05-05 | 吉林华康药业股份有限公司 | Pharmaceutical composition for preventing and treating new coronavirus infection, and medicine and application thereof |
| CN116637158A (en) * | 2023-06-02 | 2023-08-25 | 陕西中医药大学第二附属医院 | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101322810B (en) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919961B (en) | Drug composition for treating cold and preparation method thereof | |
| CN101322810B (en) | Chinese traditional medicine composition for treating diabetes respiratory tract infection | |
| CN102805776B (en) | Traditional Chinese medicine composition and preparation method of traditional Chinese medicine composition | |
| CN101700290B (en) | Pharmaceutical composition for preventing and treating warm-heat diseases of livestock and poultry and preparation method thereof | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN103316086A (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| CN100531757C (en) | Medicinal composition for treating anemopyretic cold and its preparation method | |
| CN100502916C (en) | Antivirus medicinal composition and preparation method thereof | |
| CN102139051A (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN102698158A (en) | Traditional Chinese medicine for preventing and treating infectious bronchitis, preparation method thereof and feed | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN101411752A (en) | Granular formulation for treating children's pneumonia | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN101849996A (en) | Three-drug adder-wort powder and preparation method thereof | |
| CN101721437B (en) | Preparation method of pharmaceutical composition for treating chronic pharyngitis | |
| CN101584851B (en) | Pharmaceutical composition for kidney nourishing, heart calming and nerve calming | |
| CN105232759A (en) | Pharmaceutical composition for rhinitis treatment and preparation method thereof | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN100435817C (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN109663012A (en) | Dispelling wind and heat, removing toxic substances relieving sore-throat Chinese medicine composition and the preparation method and application thereof | |
| CN103585225B (en) | The application of a kind of Herba of Artemisiae admsii extract in preparation antiviral drugs | |
| CN104042928A (en) | Pharmaceutical composition for treating diabetes and its preparation method and use | |
| CN101485757B (en) | Chinese medicinal composition for treating children's exogenous fever and preparation method thereof | |
| CN101607009B (en) | A pharmaceutical composition for treating common cold | |
| CN100579539C (en) | Chinese medicine preparation for preventing upper respiratory tract infection and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |